Page 63 - Drug Class Review

Drug Effectiveness Review Project
Alzheimer classification: Mild to moderate
Groups similar at baseline: Yes

Health Outcome Measures:

donepezil placebo 75 76 60 58 NR NR 15% 18% 4% 4% 19 19 Primary Outcome Measures: Entry to institutionalized care; progression of disability defined by loss of 2 of 4 basic or 6 of 11 instrumental activities on the BADLS Secondary Outcome Measures: Functional ability measured by the BADLS; NPI; MMSE; compliance (defined as dropouts); death from AD Timing of assessments: Baseline and every 12 weeks during treatment No significant difference observed between DON and placebo in rates of institutionalism (9% vs. 14% at 1 year; P = 0.15; 42% v

• • • • • • •

Final Report Update 1 Authors: AD2000 Collaborative Group Year: 2004 POPULATION CHARACTERISTICS: Median age (years): Sex (% female): Ethnicity: Other germane population qualities: VaD • Parkinsonism • Median baseline MMSE • OUTCOME ASSESSMENT: RESULTS: Alzheimer's Drugs